Press Releases

Date Title
Toggle Summary vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions
HIGH POINT, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th
View HTML
Toggle Summary vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
HIGH POINT, N.C. , May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns
View HTML
Toggle Summary vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
HIGH POINT, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020 , and provided an update on recent clinical achievements. “In spite of the challenges presented by the COVID-19 pandemic, we are
View HTML
Toggle Summary vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range HIGH POINT, N.C. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor conference call today at 8:30 a.m. ET HIGH POINT, N.C. , Feb.
View HTML
Toggle Summary vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
Company will Release Results on Monday, February 10th at 7:00am Followed by an Investor Call Starting at 8:30am ET HIGH POINT, N.C. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2
View HTML
Toggle Summary vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general
View HTML
Toggle Summary vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT, N.C. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
HIGH POINT, N.C. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City on Tuesday,
View HTML
Toggle Summary vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose HIGH POINT, N.C. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase
View HTML